Codexis Finalizes Purchase Agreement With Crosswalk Therapeutics For Gene Therapy Assets; Codexis Is Eligible To Receive Future Development And Commercial Milestone Payments In Addition To A Low-To-Mid Single-Digit Percentage Net Sales-Based Royalty
Portfolio Pulse from Benzinga Newsdesk
Codexis, Inc. (NASDAQ:CDXS) has entered into an asset purchase agreement with Crosswalk Therapeutics for its investigational Fabry and Pompe disease compounds. Codexis is eligible for future development and commercial milestone payments, as well as a low-to-mid single-digit percentage net sales-based royalty.
July 01, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Codexis has finalized an agreement with Crosswalk Therapeutics for its investigational Fabry and Pompe disease compounds. This deal includes future milestone payments and royalties, which could positively impact Codexis' revenue streams.
The agreement with Crosswalk Therapeutics provides Codexis with potential future revenue streams through milestone payments and royalties. This is likely to be viewed positively by investors, as it enhances the company's financial prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100